Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
View/ Open
Author
Cameron-Vendrig, Alison
Reheman, Adili
Siraj, M. Ahsan
Xu, Xiaohong Ruby
Wang, Yiming
Lei, Xi
Afroze, Talat
Shikatani, Eric
El-Mounayri, Omar
Noyan, Hossein
Weissleder, Ralph
Ni, Heyu
Husain, Mansoor
Published Version
https://doi.org/10.2337/db15-1141Metadata
Show full item recordCitation
Cameron-Vendrig, Alison, Adili Reheman, M. Ahsan Siraj, Xiaohong Ruby Xu, Yiming Wang, Xi Lei, Talat Afroze, et al. 2016. “Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.” Diabetes 65 (6): 1714–23. https://doi.org/10.2337/db15-1141.Abstract
Short-term studies in subjects with diabetes receiving glucagon-like peptide 1 (GLP-1)-targeted therapies have suggested a reduced number of cardiovascular events. The mechanisms underlying this unexpectedly rapid effect are not known. We cloned full-length GLP-1 receptor (GLP-1R) mRNA from a human megakaryocyte cell line (MEG-01), and found expression levels of GLP-1Rs in MEG-01 cells to be higher than those in the human lung but lower than in the human pancreas. Incubation with GLP-1 and the GLP-1R agonist exenatide elicited a cAMP response in MEG-01 cells, and exenatide significantly inhibited thrombin-, ADP-, and collagen-induced platelet aggregation. Incubation with exenatide also inhibited thrombus formation under flow conditions in ex vivo perfusion chambers using human and mouse whole blood. In a mouse cremaster artery laser injury model, a single intravenous injection of exenatide inhibited thrombus formation in normoglycemic and hyperglycemic mice in vivo. Thrombus formation was greater in mice transplanted with bone marrow lacking a functional GLP-1R (Glp1r(-/-)) compared with those receiving wild-type bone marrow. Although antithrombotic effects of exenatide were partly lost in mice transplanted with bone marrow from Glp1r(-/-) mice, they were undetectable in mice with a genetic deficiency of endothelial nitric oxide synthase. The inhibition of platelet function and the prevention of thrombus formation by GLP-1R agonists represent potential mechanisms for reduced atherothrombotic events.Terms of Use
This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAPCitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384218
Collections
- HMS Scholarly Articles [17878]
Contact administrator regarding this item (to report mistakes or request changes)